Research programme: oral influenza therapeutics - TSRLAlternative Names: TSR-026; TSR-462
Latest Information Update: 26 Jun 2014
At a glance
- Originator TSRL
- Class Guanidines; Pyrans; Sialic acids
- Mechanism of Action Neuraminidase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
- Available For Licensing Yes - Influenza virus infections
Highest Development Phases
- Preclinical Influenza virus infections